Drug intelligence / Profile preview

Super NK cells

Development stage: Preclinical
Lead developer: NKGen Biotech, Inc.
Modality: CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

Super NK cells represent an advanced form of natural killer (NK) cell therapy, designed as an immunotherapy for various cancers. These enhanced immune cells are engineered to provide a superior tumor-killing mechanism compared to conventional approaches. Unlike personalized CAR-T cell therapies, Super NK cells offer an off-the-shelf, allogeneic solution, aiming to minimize early immunological adverse reactions. This approach leverages the body's innate immunity to target and eliminate cancer cells, with potential applications in hematological cancers and other malignancies.

Other names: Super NK cells

Beyond the preview

Go deeper on Super NK cells.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Super NK cells.

Explore the full profile